AderintoNOlatunjiGKokoriESikirullahiSAbojeJEOjaboRE.A perspective on Oxford’s R21/Matrix-M™ malaria vaccine and the future of global eradication efforts. Malar J. 2024;23(1):16. doi:10.1186/s12936-024-04846-w
2.
DatooMSNatamaMHSoméA, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet (London, England). 2021;397(10287):1809-1818.
3.
DatooMSDickoATintoH, et al. R21/Matrix-M Phase 3 Trial Group. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024;403(10426):533–544. doi: 10.1016/S0140-6736(23)02511-4.
RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31-45.
